RecruitingNCT06698510
Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study
Studying Schistosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peter Steinmann
- Principal Investigator
- Peter Steinmann, PhD PDSwiss Tropical & Public Health Institute
- Intervention
- Arpraziquantel 150mg dispersible tablet(drug)
- Enrollment
- 18500 enrolled
- Eligibility
- All sexes
- Timeline
- 2024 – 2026
Study locations (7)
- Programme National de Lutte Contre les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CP), Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle (MSHPCMU), Abidjan, Côte d’Ivoire
- Université Félix Hophouët-Boigny (UFHB), Département de sociologie, Abidjan, Côte d’Ivoire
- Université Félix Hophouët-Boigny (UFHB), UFR Biosciences, Abidjan, Côte d’Ivoire
- African Institute for Health and Development (AIHD), Nairobi, Kenya
- Kenya Medical Research Institute (KEMRI), Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), Nairobi, Kenya
- Makerere University, Department of Sociology and Anthropology, Kampala, Uganda
- Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health, Kampala, Uganda
Collaborators
Technical University Munchen · Makerere University · African Institute for Health and Development, Kenya · Kenya Medical Research Institute · Kenya Ministry of Health · Ministry of Health, Uganda · Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle · Université Félix Hophouët-Boigny · Unlimit Health
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06698510 on ClinicalTrials.govOther trials for Schistosomiasis
Additional recruiting or active studies for the same condition.